GlassScriptPhysician profile
Abraham Hussein Abdulhak
NPI 1548752793
$7,937.90
in general payments reported to CMS, 2019-2025
20 companies · $6,209 in 2025
The $6,209 reported for 2025 was more than what 94% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $235 · 2021: $487 · 2022: $166 · 2023: $437 · 2024: $197 · 2025: $6,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,735 · Food and Beverage: $1,093 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,735.00 |
| Food and Beverage | $1,092.88 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $5,820.74 | 2025 | Libtayo |
| Abbvie INC. | $390.65 | 2019-2025 | |
| Janssen Biotech, INC. | $302.55 | 2019-2021 | |
| Kerecis Limited | $199.80 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Genzyme Corporation | $198.75 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $156.65 | 2020-2021 | |
| Galderma Laboratories, L.P. | $128.80 | 2025 | Nemluvio |
| Krystal Biotech INC | $125.00 | 2023 | Vyjuvek |
| Amgen INC. | $118.52 | 2023 | Otezla |
| Novartis Pharmaceuticals Corporation | $104.13 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.62 | 2022 | |
| Organogenesis INC. | $80.51 | 2025 | Puraply Wound Matrix |
| Genentech USA, INC. | $43.44 | 2023-2024 | Xolair, Erivedge |
| Regeneron Healthcare Solutions, INC. | $37.06 | 2024-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $31.77 | 2024-2025 | Taltz, Ebglyss |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $26.65 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $25.27 | 2024 | Sotyktu |
| Integra Lifesciences Corporation | $19.38 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Helsinn Therapeutics (U.S.), INC. | $16.86 | 2021 | |
| Pfizer INC. | $13.75 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Abdulhak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.